Literature DB >> 16836560

Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain.

Rocio González1, José Manuel Echevarria, Ana Avellón, Luisa Barea, Emma Castro.   

Abstract

BACKGROUND: Mathematical models predict that, in Spain, a significant number of blood units will be obtained during the window period of the hepatitis B virus (HBV) infection. Routine nucleic acid testing (NAT) on individual blood units may provide experimental data to evaluate such a theoretical risk. STUDY DESIGN AND METHODS: Between February and July 2005, a total of 34,631 individual units were screened for HBV DNA by a multiplex transcription-mediated amplification (TMA) test. Units that repeatedly reacted in the test, but did not react for HBV surface antigen (HBsAg), were submitted to additional testing by both molecular and conventional assays, and the donors were recalled for follow-up studies and the collection of clinical and epidemiologic data.
RESULTS: Confirmatory testing and follow-up studies identified 2 blood units donated during the HBV infection window period (1/17,316 units studied). Sequencing of amplification products obtained by nested polymerase chain reaction (n-PCR) revealed two HBV strains from genotypes D/ayw3 and F/adw4q-, but did not identify HBsAg mutants. The HBV DNA concentration in the index donations was estimated to be below the n-PCR detection level (180 IU/mL), in both cases. One donor developed acute hepatitis 2 months after donating blood, but the other remained asymptomatic and displayed normal alanine aminotransferase levels at follow-up.
CONCLUSIONS: The HBV infection window period is a real issue in the setting of Spanish blood transfusions. NAT of individual units by TMA would make a significant contribution to improving the safety of the blood supply in Spain. Additional studies involving a larger number of units and longer periods of time are required, however, to ascertain the true incidence of the problem in this country.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16836560     DOI: 10.1111/j.1537-2995.2006.00863.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.

Authors:  Moon Jung Kim; Quehn Park; Hyuk Ki Min; Hyun Ok Kim
Journal:  BMC Infect Dis       Date:  2012-07-20       Impact factor: 3.090

2.  Sufficient blood, safe blood: can we have both?

Authors:  Halvard Bönig; Michael Schmidt; Kai Hourfar; Jörg Schüttrumpf; Erhard Seifried
Journal:  BMC Med       Date:  2012-03-23       Impact factor: 8.775

Review 3.  Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management.

Authors:  Lung-Yi Mak; Ian Beasley; Patrick T F Kennedy
Journal:  Sports Med Open       Date:  2022-10-04

4.  Automated identification of acute hepatitis B using electronic medical record data to facilitate public health surveillance.

Authors:  Michael Klompas; Gillian Haney; Daniel Church; Ross Lazarus; Xuanlin Hou; Richard Platt
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.